|
J Biol Chem, Vol. 273, Issue 32, 20228-20237, August 7, 1998
Distinct Subdomains of the EphA3 Receptor Mediate Ligand Binding
and Receptor Dimerization*
Martin
Lackmann ,
Andrew C.
Oates §,
Mirella
Dottori¶,
Fiona M.
Smith¶,
Cuong
Do ,
Maryanne
Power¶,
Lucy
Kravets , and
Andrew W.
Boyd¶
From the Ludwig Institute for Cancer Research
(Melbourne Branch), Post Office, Royal Melbourne Hospital,
Victoria 3050 and the ¶ Queensland Institute for Medical
Research, The Bancroft Centre, Post Office, Royal Brisbane Hospital,
4029 Queensland, Australia
 |
ABSTRACT |
Eph receptor tyrosine kinases and their ligands
(ephrins) are highly conserved protein families implicated in
patterning events during development, particularly in the nervous
system. In a number of functional studies, strict conservation of
structure and function across distantly related vertebrate species has
been confirmed. In this study we make use of the observation that
soluble human EphA3 (HEK) exerts a dominant negative effect on somite
formation and axial organization during zebrafish embryogenesis to
probe receptor function. Based on exon structure we have dissected the extracellular region of EphA3 receptor into evolutionarily conserved subdomains and used kinetic BIAcore analysis, mRNA injection into zebrafish embryos, and receptor transphosphorylation analysis to study
their function. We show that ligand binding is restricted to the
N-terminal region encoded by exon III, and we identify an independent,
C-terminal receptor-dimerization domain. Recombinant proteins encoding
either region in isolation can function as receptor antagonists in
zebrafish. We propose a two-step mechanism of Eph receptor activation
with distinct ligand binding and ligand-independent receptor-receptor
oligomerization events.
 |
INTRODUCTION |
The Eph family of receptors signal by binding cell-surface
proteins known as ephrins. Cell contact is thought essential for this
process, as only membrane-associated or artificially clustered forms of
the ephrins, which mimic cell-cell apposition, can cause receptor
transphosphorylation and activation (1-3). Inferred from sequence
homologies, the structure of the Eph family is typified by an
extracellular domain (ECD)1
comprising an N-terminal, cysteine-rich region, an EGF-like motif, and
two fibronectin III repeats (4-6); however, the structural requirements and mechanism of receptor activation remain to be elucidated.
Studies measuring Eph/ephrin binding affinities using artificially
clustered receptor ECDs suggest that Eph receptors and ephrins fall
into the following two groups: EphA receptors interact preferentially
with glycosylphosphatidylinositol-linked ephrins (ephrin-A), whereas
those interacting preferentially with transmembrane ligands (ephrin-B)
are called EphB receptors (7). Within each group, Eph receptors display
cross-reactivity with multiple ephrins (1, 8-12). However, receptors
and ligands within a class do not show equivalent affinities, but
rather display a distinct ordering (3, 12-14). These findings are in
keeping with the specialized roles in the development of the visual
system, observed for EphA3 receptors (MEK4/CEK4) and ephrin-A2 (ELF1)
and -A5 ligands (AL1/RAGS) (14-18). Very similar functional and
structural characteristics have been described for the zebrafish ephrin
zEphL4, suggesting it as the orthologue of ephrin-A5 (19).
The activation mechanisms for a number of other RTK subfamilies have
been elucidated. These include dimerization/activation of individual
class I receptor chains through conformational changes upon binding of
soluble ligands, ligand-induced activation of preassociated,
disulfide-stabilized heterotetrameric type II receptors, and ligand
dimer-induced activation of type III receptors (reviewed in Ref. 20).
Both monomeric and dimeric ligands are known to induce rapid receptor
dimerization, and for some monovalent RTK ligands, the critical role of
an intrinsic receptor dimerization interface for receptor activation
and biological function has been demonstrated (21). Little is known
about the composition of Eph·ephrin signaling complexes. Importantly,
the demonstration of stable human EphA3·ephrin-A5 complexes in
solution, revealing a strict 1:1 stoichiometry (3), the ability of
soluble forms of ephrin-A5 to act as a signaling antagonist (2), and
the notion of distinct signaling pathways for dimeric and higher
oligomeric receptor complexes (22) suggest that models of
dimerization/activation for other RTK may not adequately describe the
formation of active signaling complexes for Eph receptors.
To understand further Eph/ephrin interactions and the mechanisms of Eph
receptor activation, we dissected the human EphA3 (h-EphA3) ECD into
structural subdomains, and through BIAcore analysis we identified a
unique N-terminal domain that is sufficient for h-ephrin-A5 (LERK7)
binding. By adopting a dominant negative approach to disrupt zebrafish
embryogenesis (23, 24), we confirmed the function of the ligand-binding
domain in vivo. The same approach allowed characterization
of a distinct C-terminal domain which mediates ligand-independent
dimerization of the EphA3 ECD. The role of these two domains in
receptor activation was confirmed in transphosphorylation assays. By
taking into account the 1:1 stoichiometry of the h-EphA3/h-ephrin-A5
interaction (3), the "mass action" model suggested by Nakamoto
et al. (17) from functional studies, the receptor
dimerization mechanism of the PDGF receptors (25), and the data
presented here, we propose a stepwise receptor activation mechanism. In
our model, high affinity interactions between ephrin-A on the leading
edge of migrating cells and the N-terminal ligand binding domain of
EphA receptors on opposing cells leads to clustering of EphA receptors.
A sufficiently high local concentration of ephrin-A will facilitate
accumulation of receptors to a critical concentration that triggers
oligomerization through their C-terminal receptor/receptor interaction
domain and leads to receptor transphosphorylation and signal
transduction.
 |
MATERIALS AND METHODS |
Isolation and Mapping of hEphA3 Genomic Clones--
The h-EphA3
cDNA probes used to screen the human genomic libary were PCR
fragments amplified from plasmids containing full-length h-EphA3
cDNA. The primers used were probe A (spans 74-1161 bp as
described by Wicks et al. (58) GTAGGAATTCCTCTCACTGCCCTCTGC and GTAGGGATCCGGCCTCCTGTTCCAG, probe B (1053-1124 bp)
GTAGGAATTCCATGG CTTGTACCCGAC and GTAGGGATCCCATAATGCTTGCTTCTC, probe C
(2-186 bp) ATGG ATGGTAACTTCTCCAG and TCATTGGAAGGCTGCGGAAT, and probe D
(spans 909-1404 bp) GTAGTCTAGACAAGCTTGTCGACCAGGTTT and
GTAGTCTAGATCAAGCCTGATTAGTTG TGATGC. The mouse genomic library was
screened with a MEK4 fragment cut from a plasmid subcloned with MEK4
cDNA (kindly provided by E. Pasquale, University of California, San
Diego). The cDNA fragment spans 582-899 bp of MEK4 sequence
(26).
The genomic libraries used were as follows: human in FIX II vector
(Stratagene Cloning Systems, La Jolla), mouse in FIX II vector
(Stratagene), and DASH II vector (kindly provided by F. Köntgen). Approximately 106 plaques from each library
were screened by high stringency hybridization with radiolabeled probes
as described above. Positive clones were identified by autoradiography,
purified by subsequent screenings, and isolated using standard
methodology (27). Exon-intron boundaries were determined by a
combination of direct DNA sequencing, PCR, restriction analyses, and
Southern blotting. Direct DNA sequencing of the genomic phages and
subcloned plasmid was performed using the ABI 373 DNA sequencer
(Applied Biosystems, Melbourne, Australia). Sequencing and PCR primers
used to characterize the h-EphA3 gene from human genomic clones were
based on the h-EphA3 cDNA sequence.
The exons found within the mouse genomic clones were amplified by PCR
using degenerate primers specific to EPH-like RTKs, GTAGGCATGCAAGGAGA
C(AC)TT(CT)AACC and CC(AG)ATGGGNACCAGCCA(CT)TC. The PCR products were
then directly sequenced as described above (Applied Biosystems) using
the degenerate primers.
Production of sh-EphA3 and sh-EphA3 Subdomains in CHO
Cells--
The h-EphA3 ECD and N-terminally FLAG-tagged h-EphA3
proteins were prepared from transfected Chinese Hamster ovary (CHO)
cell supernatants as described (3, 28). Deletion mutants of h-EphA3 were prepared by PCR using oligos based on the exon boundaries. h-EphA3
III and IV were constructed using a 5' oligo based on the the N
terminus of the mature protein (29) with a 5' XbaI site
(GTAGTCTAGAGAACTGATTCCGCAGCCTTCCAA) and 3' oligos based on sequences
spanning exon IV (GTAGTCTAGATCATGGAGGTCGGGTACAAGC) and 3 (GTAGTCTAGATCAAGCTTGGCACATAAAACCTC), respectively, followed by a stop
codon and an XbaI site. Construct IX used a 5' oligo designed to span the 5' end of exon IV with a 5' XbaI site
(GTAGTCTAGACAAGCTTGTCGACCAGGTTTC) and a 3' oligo based on the C
terminus of the exodomain with a stop codon and flanking
XbaI site (GTAGTCTAGATCATTGGCTACTTTCACC AGAG). In each case
the PCR products were cloned into the interleukin-3 signal-FLAG-pEFBOS
vector as described previously (3, 28). DNA was electroporated into CHO
cells, and high producer clones were selected by "dot blot"
screening of culture supernatants on polyvinylidene difluoride
membranes and the expected size of the recombinant proteins confirmed
by SDS-PAGE and Western blot analysis using M2 anti-FLAG mAb and rabbit
anti-mouse AP-tagged mAb for detection by enhanced chemiluminescence
(ECL; Amersham).
Deletion mutants were purified on M2 anti-FLAG affinity columns and
eluted with FLAG peptide according to the manufacturer's instructions.
Homogenous preparations (>95% by SDS-PAGE and silver staining) were
obtained by anion exchange (Mono Q, 5 × 50 mm, Pharmacia,
Uppsala, Sweden) and size exclusion chromatography (Superose 12, 10 × 300 mm, Pharmacia, Uppsala, Sweden). The identity and
concentration of the purified h-EphA3 proteins in the final preparations were confirmed by N-terminal amino acid sequence analysis
and amino acid analysis, and where applicable, their native
conformation was confirmed on the BIAcore as described (28).
Production of FLAG-tagged Ephrin-A5--
h-Ephrin-A5 containing
an N-terminal FLAG peptide was purified from transfected CHO cells and
tested for its specific binding to sh-EphA3 as described (3).
Synthesis of sh-EphA3-derived Peptides--
The peptides
according to the amino acid sequence encompassing residues
Glu1 to Gly31 (h-EphA3 1-31) of sh-EphA3 was
assembled by solid-phase peptide synthesis according to standard
protocols, purified by reverse phase-high pressure liquid
chromatography, and their masses confirmed by mass spectrometry.
Analysis of the Interaction between sh-EphA3 Constructs and
Ephrin-A5--
The binding of various h-EphA3 constructs and derived
peptides was analyzed on the BIAcore optical biosensor (Pharmacia
Biosensor, Sweden) using purified h-EphA3 ECD or
ephrin-A5-FLAG-derivatized CM 5 sensor chips, and the interaction
kinetics were determined as described (3). For the analysis of the
binding of the h-EphA3 constructs to h-EphA3 (subdomain)-derivatized
sensor surfaces, difference sensorgrams were derived by subtraction of
the response on a parallel channel containing a non-relevant protein as
described (28). The effect of h-EphA3-derived peptides on the
interaction of h-EphA3 with ephrin-A5 was tested by incubating a
constant concentration of the ligand with increasing amounts of peptide prior to analysis on a h-EphA3 ECD-derivatized sensorchip. The affinity
surface was regenerated between subsequent injections of samples with a
35-µl injection of 50 mM 1,2-diethylamine, 0.1% Triton
X-100, followed by two washes with BIAcore running buffer (Hepes
buffered saline, 0.005% Tween 20).
Fish Care and Embryo Collection--
Wild type zebrafish were
obtained from St. Kilda Aquarium (Melbourne, Australia) and were kept
essentially as described (30). Embryos were obtained by natural
spawning between a small number (4-10) of male and female fish.
Embryos were removed from the spawning tanks within 20 min of
fertilization, cleaned in system water, and transferred to the
injection apparatus.
RNA Synthesis--
Constructs equivalent to full-length h-EphA3
ECD (h-EphA3 I-VII) and h-EphA3 IV-VII were generated by PCR from the
constructs described above. In each case the 5' oligo was based on the
interleukin-3 signal sequence and the 3' oligos were as above except
that BglII sites were used to clone the PCR products into
the pSP64TK vector. mRNA from the h-EphA3 constructs and a control
E-GFP cDNA construct were transcribed in vitro using the
mMessage mMaker kit (Ambion, Texas) and resuspended in water at a
concentration of 0.1 mg/ml in small aliquots. Integrity of the RNA was
checked by denaturing gel electrophoresis of the resulting products.
Immediately prior to injection, aliquots of h-EphA3 I-III, h-EphA3
I-IIV, or h-EphA3 IV-VII were thawed and mixed with water and E-GFP
mRNA to a final concentration such that either 100, 10, or 1 pg of
the receptor mRNA and 5 pg of the E-GFP mRNA were delivered to
each embryo.
RNA Microinjection--
Approximately 600 pl of RNA dissolved in
water at various concentrations was injected into one, two, or four
cell embryos under a Wild stereo microscope using Leitz
micromanipulators (Leitz, Wetzlar, Germany) and compressed nitrogen.
The needle was positioned under the blastoderm in the region of
cytoplasmic streaming. Successful injection was judged in the first
instance by a visible bolus of fluid in the embryo. Uptake and
translation of mRNA by the embryo was measured by including 5 pg of
mRNA encoding E-GFP as a marker in each injection. Injection of
over 100 pg of E-GFP mRNA per embryo does not cause developmental
defects. The translation of the injected h-EphA3 mRNA was measured
at intervals during embryogenesis by Western blotting and BIAcore
analysis.
Western Blot and BIAcore Analysis of Zebrafish Lysates--
Ten
embryos per sample were lysed in embryo lysis buffer (0.1 ml, 25 mM Tris-HCl, pH 7.4, 0.5 M NaCl, 1% Triton
X-100), and the lysate was cleared by centrifugation (60 min, 1 × 105 × g) and stored at 80 °C until use.
For comparison, CHO cell-derived h-EphA3 I-VII and subdomain
constructs (as indicated) were added to zebrafish lysate, and all
samples were extracted individually using 7.5 µl of packed anti-FLAG
(M2) agarose (IBI, Kodak), washed (0.5 ml each) with lysis buffer and
buffer, and eluted from the affinity resin with 2 × 15 µl of
0.15 mg/ml FLAG peptide in buffer. Parallel samples were either
separated by SDS-PAGE, electroblotted and probed with biotinylated
anti-FLAG M2 mAb (IBI, Kodak) followed by horseradish
peroxidase-derivatized streptavidin (Boehringer Mannheim) for enhanced
chemiluminescence detection (ECL, Pierce), or analyzed on the BIAcore.
For BIAcore experiments, sensorchips were derivatized with anti h-EphA3
mAb IIIA4 as described (28). Lysates of zebrafish embryos which had
been injected with h-EphA3 I-III RNA or h-EphA3 IV-VII RNA were
analyzed in parallel, and the amount of sh-EphA3 I-III and sh-EphA3
IV-VII quantitated by comparison to known amounts analyzed in parallel
samples. A linear correlation (r = 0.998) between
increasing concentration of added protein and BIAcore response was
obtained routinely.
Analysis of Developmental Defects--
The effects on embryonic
growth of each of the injected mRNAs was measured in two ways.
Embryos were allowed to grow for 12-13 h after fertilization (five to
eight somite stage (31)); their gross morphology was noted under a
dissecting microscope, and the perturbation of early patterning gene
expression was assayed by in situ hybridization using
DIG-labeled RNA probes. Embryos were scored as defective if a typical
pattern of gene expression was disrupted.
Transphosphorylation Assays--
Soluble forms of the h-EphA3
receptor representing combinations of subdomains (exons I-VII, exons
I-III, exons IV-VII, and exons V-VII) were incubated with M2
anti-FLAG antibody in a 2:1 molar ratio to allow cross-linking of two
h-EphA3 subdomain proteins. Phosphorylation of LK63 cells (32) with
preformed complexes of M2 antibody and soluble recombinant proteins was
done as described (3). The lysates were initially immunoprecipitated
with protein A-Sepharose for 30 min at 4 °C. The lysate was removed
from the beads and transferred onto IIIA4 anti HEK-Trisacryl beads
(Sepracor/IBF, Villeneuve la Garenne, France), and a second round of
immunoprecipitation was carried out for 2 h at 4 °C as
described previously (3). Both the protein A and IIIA4 beads were
washed three times in phosphate-buffered saline with 0.05% Tween 20 and 0.1 mM orthovanadate. The immunoprecipitates were
subjected to 7.5% SDS-PAGE and electroblotted onto Hybond ECL
nitrocellulose membranes (Amersham, Australia). The Western blots were
probed using an anti-phosphotyrosine mAb (PY20, ICN Immuno-Biologicals,
Costa Mesa, CA) and developed using the ECL Western blot analysis kit
(Amersham, Australia). The membranes were stripped and re-probed with a
rabbit polyclonal antiserum raised against h-EphA3 (rabbit
anti-HEK).
 |
RESULTS |
Expression of Receptor ECD Subdomains--
To analyze the
structural basis of the h-EphA3 receptor/ephrin-A5 ligand interaction
and receptor activation, we analyzed the function of isolated
subdomains derived from the complete h-EphA3 ECD. For the design of
stable subdomains, we analyzed the h-EphA3 gene structure and found
that exon-intron boundaries of h-EphA3 ECD genomic clones aligned with
clones of the mouse EphA4 (SEK1), EphA5 (BSK), and EphA1 (ESK)
genes.2 Together with data on
the chicken EphB2 (CEK5) gene (33) and splice variants of other
Eph-like RTK (26, 34), this suggests a highly conserved exon structure
within the Eph subfamily (Fig. 1a). Comparison of ECD
sequences of h-EphA3 and its mouse (MEK4) and chicken (CEK4) homologues
(26) demonstrates the highest amino acid sequence identity (99.5 and
98.3%, respectively) is found in the exon III-encoded domain (Fig.
1b). The structure of the domain encoded by exons II and III
was analyzed in detail, addressing previous reports that this region
consisted of an N-terminal Ig-like domain and a C-terminal
cysteine-rich region. Sequence data base comparisons and alignment of
the h-EphA3 exon II and III sequences with known C1, C2, and V set Ig
domains and a number of EGF domains using the ALIGN program (35) showed
features of the C-terminal half of an EGF domain in the most C-terminal exon III-encoded region, but no homology more N-terminally, whereas homology to an Ig-like motif was not found within this region.

View larger version (24K):
[in this window]
[in a new window]
|
Fig. 1.
Genomic organization of the ECD of EPH-like
RTK genes and identification of the ligand-binding subdomain.
a, exon structure of the h-EphA3 ECD; exon I contains the
first 88 bp of the coding sequence including the signal peptide, and
together with exon II encodes the first 31 residues of the mature
protein (58). Exon III encodes 10 of the 20 conserved cysteine residues
characteristic of this subfamily. Sequence alignment (59) suggested no
significant homology between exon III and known protein domains,
although the C terminus of exon III contains the
CnCXCXXGYnC motif
reminiscent of the C terminus of an EGF-like domain (33, 60). Exon IV
shows an unambiguous EGF consensus (60), and exon V and exons VI and
VII together match the previously defined fibronectin domains (61). The
sequences for intron-exon splice junctions matched with the "GT-AG"
rule (62). A clone containing h-EphA3 exon II was not obtained, and its
boundaries were inferred from the 5' and 3' junctions of exon I and exon
III, respectively. Introns interrupting h-EphA3 cDNA coding
sequence as described (58) were found to occur at 89 bp (5' of exon
II), 155 bp (5' of exon III), 817 bp (5' of exon IV), 974 bp (5' of
exon V), 1311 bp (5' of exon VI), 1438 bp (5' of exon VII), and 1601 bp
(5' of exon VIII). The exons found within the mouse genomic clones of
SEK1, BSK, and ESK were found to have identical borders as h-EphA3 with
respect to the protein coding sequence. b, ECD subdomains
according to the exon structure of sh-EphA3, depicted in Fig.
2a. The domains are illustrated as differently shaded
bars: , exons I and II; , exon III; , exon IV; , exon
V; , exons VI and VII. c, recombinant h-EphA3 proteins,
encoded by exons I-VII, I-IV, I-III, IV-VII, and produced as
described under "Materials and Methods" were analyzed by SDS-PAGE
and silver staining. The doublet bands of h-EphA3, h-EphA3 I-VII, and
h-EphA3 IV-VII are due to glycosylation heterogeneity.3 In
CHO cells appreciable expression levels and the expected apparent
molecular sizes were found for h-EphA3 I-VII (the FLAG-tagged version
of h-EphA3 encoded by exons 1-7, 68 kDa), h-EphA3 I-IV (36 kDa),
h-EphA3 I-III (33 kDa), h-EphA3 IV-VII (40 kDa), and h-EphA3 V-VII
(36 kDa, not shown). d, association rate constants ( ),
derived from BIAcore raw data using the BIA evaluation software for the
binding of h-EphA3 subdomain proteins (15.6-500 nM) to
h-ephrin-A5-derivatized sensorchips. e, apparent
dissociation constants were estimated from the kinetic rate constants
according to KD = kd/ka. The mean and standard
deviation from estimates at five different concentrations are shown
( ). In addition, equilibrium responses were used to estimate the
apparent equilibrium dissociation constants ( ). f,
samples containing 40 nM h-ephrin-A5 and 1 nM
to 10 µM of a synthetic peptide according to the h-EphA3
sequence encoded by exons I and II ( ), 1 nM to 1 µM sh-EphA3 I-III ( ), 10 nM to 5 µM sh-EphA3 IV-VII (×), or 10 nM to 1 µM sh-EphA3 I-VII ( ) were injected onto a
sh-EphA3-derivatized sensorchip. The residual responses are illustrated
as percent of total response in the absence of competitor.
|
|
The defined exon boundaries were used to demarcate cDNA domain
deletion mutants of the h-EphA3 ECD for expression as FLAG epitope-tagged proteins in CHO cells (Fig. 1c) and,
following in vitro transcription into mRNA, for
expression in zebrafish embryos (Fig. 2).
The proteins are identified throughout by roman numbers according to
their corresponding exons. The exon III- and exon IV-encoded portions
of the h-EphA3 receptor correspond to domains described as globular and
cysteine-rich domains in a recent report on the functional dissection
of the EphB2 receptor (36). Thus, the FLAG fusion proteins h-EphA3
I-III, h-EphA3 I-IV, and h-EphA3 VI-VII directly relate to the
EphB2-alkaline phosphatase (AP) fusion proteins "280-AP,"
"331-AP," and "CEK5 Glob-AP" (which includes an exon
III-encoded part), respectively (36).

View larger version (21K):
[in this window]
[in a new window]
|
Fig. 2.
Expression of exogenous h-EphA3 I-VII,
h-EphA3 I-III, and h-EphA3 VI-VII in zebrafish embryos by Western
blot and BIAcore analysis. a, samples of 12 hpf zebrafish
lysate (10 embryos/0.1 ml) containing defined amounts of CHO
cell-derived h-EphA3 I-VII, h-EphA3 I-III, and h-EphA3 IV-VII were
immunoprecipitated with anti-FLAG mAb (M2) agarose and analyzed by
Western blots with anti-FLAG mAb, visualized by enhanced
chemiluminescence (lanes 1-3). Zebrafish embryos injected
with 10 pg of either h-EphA3 I-VII, h-EphA3 I-III, or h-EphA3 IV-VII
mRNA were lysed after 5 or 10 h (10 embryos/0.1 ml) and
analyzed in parallel lanes of the gel (lanes 4-9).
Lanes 1 and 2, CHO cell h-EphA3 I-VII and
h-EphA3 IV-VII, 15 and 10 ng, respectively; lane 3, 10 ng
of CHO cell h-EphA3 I-III; lanes 4 and 5,
h-EphA3 I-VII RNA injections, 5 and 10 hpf; lanes 6 and
7, h-EphA3 VI-VII RNA injections; lanes 8 and
9, h-EphA3 I-III RNA injections, 5 and 10 hpf.
b, parallel samples of zebrafish lysates from h-EphA3 I-III
RNA-injected embryos (100 pg/embryo), collected 5, 10, 15, and 24 h post-fertilization were extracted on M2 agarose, and the FLAG peptide
eluate was analyzed on a BIAcore sensorchip which had been
derivatized with the conformation-specific anti h-EphA3 mAb IIIA4.
The BIAcore response was used to estimate the h-EphA3 I-III abundance
by comparison with identically treated samples of CHO cell-derived
h-EphA3 III at a known concentration.
|
|
We obtained homogenous proteins from CHO cell supernatants by anti-FLAG
affinity and size exclusion chromatography; SDS-PAGE and silver
staining of the purified proteins revealed apparent molecular sizes as
predicted from the amino acid sequence and putative glycosylation sites
(Fig. 1c). Doublet protein bands for h-EphA3, h-EphA3
I-VII, and h-EphA3 IV-VII are likely due to the glycosylation
heterogeneity of these proteins; h-EphA3 derived from transfected
glycosylation-deficient Lec4 CHO cells (37), with unchanged ability to
bind h-ephrin-A5, appear as single bands on silver-stained
SDS-PAGE.3 Interestingly, no
expression was observed for any of the protein constructs containing
the exon III-encoded domain, but lacking the first 31 amino acids of
h-EphA3 (encoded by exons I and II), suggesting impaired translation or
stability of these constructs.
Identification of the EphA3 Ligand-binding Domain--
In order to
characterize the ligand-binding region of the h-EphA3 receptor, the
individual binding affinity of each of the ECD subdomains for the
h-EphA3 ligand was assayed using an h-ephrin-A5-derivatized BIAcore
sensorchip. A kinetic analysis demonstrates high affinity interactions
for the binding of h-EphA3 I-VII (the FLAG-tagged version of the
h-EphA3 ECD encoded by exons I-VII), h-EphA3 I-IV, and h-EphA3
I-III, with affinities in the same range (Kd, 18-72 nM, Fig. 1, d and e) reported
previously for the binding of h-ephrin-A5 to sensor chip-immobilized
h-EphA3 (3). No binding of h-EphA3 IV-VII was observed at any of the
tested concentrations (16-500 nM), localizing the ligand
binding site to the exon I-III-encoded N terminus of h-EphA3. Very
similar apparent dissociation constants for the h-EphA3 ECD and h-EphA3
I-VII (72 ± 15 and 62 ± 12 nM, Fig.
1e) suggest that an N-terminal addition of the FLAG peptide has no effect on the interaction between h-EphA3 and its ligand. Substantially lower dissociation constants (i.e. higher
affinities) of 18-29 nM due to increased association rate
constants (Fig. 1d) were observed for the h-EphA3 subdomain
constructs h-EphA3 I-IV and h-EphA3 I-III. In-solution competition
with an exons I- and II-encoded synthetic h-EphA31-31
peptide, and with the FLAG-tagged h-EphA3 IV-VII construct, did not
inhibit the receptor/ligand interaction at concentrations up to 10 µM, whereas addition of h-EphA3 I-VII or h-EphA3 I-III
resulted in a dose-dependent reduction of the BIAcore
response (Fig. 1f). Taken together, these results imply that
the cysteine-rich domain encoded by exon III of h-EphA3 is necessary
and sufficient for ligand binding.
Soluble EphA3 Ligand Binding Subdomain Induces a Dominant Negative
Phenotype in Zebrafish--
To confirm the binding studies we analyzed
the effect of ectopic expression of receptor constructs h-EphA3 I-III
(ligand binding domain) or h-EphA3 IV-VII, which shows no ephrin-A5
binding, on zebrafish development. We have recently characterized
developmental defects in the formation of somite boundaries in
zebrafish embryos induced by introduction of either soluble h-EphA3 ECD
or h-ephrin-A5 as signaling
antagonists.4 A similar
dominant negative approach has been used earlier to evaluate the role
of EphA4 signaling in forebrain and hindbrain formation (23). These
authors expressed kinase domain deletion constructs of m-EphA4 in
zebrafish embryos to disrupt the function of the endogenous orthologue
by forcing heterodimerization with the exogenous mutant receptor (23,
24). In a modification of this approach, we anticipated that expression
of the h-EphA3 ligand binding domain during zebrafish development
should be sufficient to block endogenous receptor/ligand interactions
by competing for binding to endogenous ligand. On the other hand,
expression of the regions of the ECD that cannot bind ligand should not
mediate these antagonistic effects.
Thus, the effects of constructs h-EphA3 I-VII, containing the entire
ECD, h-EphA3 I-III, encompassing the ligand binding domain, and
h-EphA3 IV-VII, encompassing the remainder of the ECD (and incapable
of h-ephrin-A5 binding) on zebrafish development were analyzed. The
corresponding mRNAs, denoted h-EphA3 I-VII RNA, h-EphA3 I-III
RNA, and h-EphA3 IV-VII RNA, respectively, were introduced into
zebrafish embryos by microinjection. A widespread distribution of the
exogenous proteins throughout the embryo was observed as indicated by
the uniform expression pattern of the GFP protein (Fig.
3f). FLAG epitope-containing
proteins with the same molecular weights as the corresponding proteins
expressed in CHO cells were detected by Western blot (Fig.
2a) at similar abundance of all three constructs in the
embryos at 5 and 10 hours post-fertilization. This suggests equivalent
expression of all mRNAs throughout the time frame of the
experiment. By using the native conformation-specific, anti-h-EphA3
mAb, IIIA4 (28, 29), we quantitated the expression level of exogenous,
biologically active h-EphA3 I-III by BIAcore analysis of lysates from
zebrafish embryos, which had been injected with h-EphA3 I-III RNA
(Fig. 2b). As shown previously for h-EphA3 I-VII and
h-ephrin-A5,4 there was an initial steep rise in expression
h-EphA3 I-III leading to a plateau after 15 h (Fig.
2b).

View larger version (92K):
[in this window]
[in a new window]
|
Fig. 3.
Ectopic expression of the exon I-III- but
not of the exon IV-VII-encoded h-EphA3 subdomain affects the
development of zebrafish embryos. a-f, zebrafish
embryos, uninjected or injected with 5 pg of marker mRNA and with
10 pg of either h-EphA3 I-III or h-EphA3 VI-VII RNA during the first
two cleavage divisions, were raised at 28 °C. After 12-13 h embryos
viewed by light microscopy were photographed from a lateral perspective
in a, c, e, and f with dorsal to the right and
anterior up, and from a dorsal perspective (b and
d) with anterior up in each frame. The areas of somite
development are indicated by brackets. Embryos shown are
representative of the phenotype in groups of 29-89 embryos as
indicated in Fig. 5. a, a non-injected zebrafish embryo at
12-13 hpf showing normally developed optic vesicle, forebrain, and
tail-bud. The embryo has covered more than 3/4 of the perimeter
of the yolk cell with head and tail approaching each other. Somite
formation in the trunk in a regular, periodic pattern is indicated by
the bracket. b, dorsal view of the same embryo
revealing clearly distinguishable neuraxis and somites. The
bracket on the right-hand side
indicates a region of paraxial mesoderm that underwent somite
formation. c, a zebrafish embryo at 12-13 hpf after
microinjection with 10 ng of h-EphA3 I-III RNA displaying severe
anterior defects, including a reduced size of the optic vesicle as well
as an absence of mid- and hindbrain segmentation. The gap between the
tail region (tail bud is missing, open arrowhead) and the
head region (optic vesicle barely visible, closed arrowhead)
is widened substantially compared with the non-injected embryo
(a). The region of the trunk that normally would form
somites is indicated by the bracket (compare with
a). The dark line around perimeter of the yolk is
a photographic artifact due to the contrast needed to show the details
of somite formation in the embryo during light microscopy.
d, dorsal view of the h-EphA3 I-III RNA-injected embryo.
Comparison of the left and right sides of the
trunk region of affected embryos as indicated by the bracket
reveals heavily disorganized somite boundaries. e, a 13-hpf
embryo after injection with 10 pg of h-EphA3 I-III RNA. The morphology
of this embryos is indistinguishable from the non-injected control
shown in a. As in c, the dark line
around perimeter of the yolk is a photographic artifact due to the
contrast needed to show the details of the embryo during light
microscopy. f, the same embryo viewed under epifluorescence
illumination to illustrate the translation of co-injected E-GFP marker
mRNA demonstrating widespread and high level expression of the
exogenous proteins.
|
|
Embryos injected with 1 pg or 10 pg of sh-EphA3 I-III RNA per embryo
developed a syndrome indistinguishable from that described for the
full-length h-EphA3 I-VII RNA (Fig. 3 c and
d).4 The defects noticed in embryos between 11 and 15 h post-fertilization (hpf), by comparison with non-injected
control embryos (Fig. 3, a and b), included most
prominently a disruption of somite boundaries (Fig. 3, c and
d) coincident with a reduced height of the dorsal axis from
the surface of the yolk cell (Fig. 3c). Furthermore, a
disorganized anterior neuraxis and retarded tailbud development were
observed (Fig. 3c). To monitor nonspecific effects on
embryogenesis, which may have been caused by injection of mRNA and
expression of foreign protein, embryos were injected with E-GFP or the
soluble, FLAG-tagged ECD of deleted in colo-rectal cancer (DCC) (38), a
major guidance receptor known to be involved in embryogenesis. Although
expression of the soluble FLAG-tagged DCC construct induces a defined
nerve guidance defect in Xenopus
embryos,5 and despite high
levels of exogenous protein expression, we could not detect any
developmental defects in E-GFP or DCC mRNA-injected embryos as
judged by the criteria of our experiments (Fig. 3f and
data not shown).
The similarity of the phenotype due to h-EphA3 I-VII RNA and h-EphA3
I-III RNA injection was also evident by analysis of marker gene
expression; in situ hybridization with probes to
hlx-1 (39), paxb (40), krox20 (41),
and myoD (42) revealed abnormal patterns consistent with the
morphological defects observed in the live embryos (Fig.
4, c and d). In
particular, myoD-expressing cells were disarrayed along the
paraxial mesoderm indicating a disruption of somite formation, giving
the track formed by myoD-expressing, adaxial mesoderm cells
adjacent to the midline a distinctive twist (Fig. 4c). A
single axially located stripe of hlx-1 expression suggested
an intact ventral forebrain region. Non-injected control embryos (Fig.
4, a and b) or embryos injected with E-GFP alone (not shown) did not show these defects in the expression of
myoD. In contrast, no apparent developmental defects were
detected in embryos injected with either 1 or 10 pg of h-EphA3 IV-VII
RNA per embryo, either by gross morphological criteria (Fig.
3e) or by analysis of marker gene expression (Fig. 4,
e and f). Ubiquitous expression of the
co-injected E-GFP mRNA (Fig. 3f) and Western blot
analysis (Fig. 2a) during the period of development under analysis indicated that the protein was both widely and highly expressed.

View larger version (116K):
[in this window]
[in a new window]
|
Fig. 4.
In situ hybridization analysis of
h-EphA3 mRNA injected embryos. Embryos were left untreated
(a and b) or injected with 10 pg of either
h-EphA3 I-III RNA (c and d) or h-EphA3 IV-VII
RNA (e and f), allowed to develop for 12 to 13 hpf, and fixed for in situ hybridization with
pax-b, hlx-1, krox20, and
myoD DIG-labeled riboprobes. Embryos are photographed from a
dorsal perspective with anterior to the top and posterior to
the bottom of each frame; a, c, and e,
postero-dorsal view; b, d and f, antero-dorsal
view. a and b, uninjected embryo at 12 hpf
showing normal expression of hlx-1 in the ventral forebrain,
pax-b in the midbrain, krox20 in rhombomeres 3 and 5 of the hindbrain and myoD in the paraxial mesoderm. A
regular, serially repeated pattern of myoD staining
illustrates the somites. Cells expressing pax-b,
hlx-1, and krox20 have migrated toward the
midline and form tight bands marking forebrain (hlx-1),
midbrain (pax-b), and hindbrain (krox20).
c and d, h-EphA3 I-III RNA (10 pg)-injected
embryo at 12 hpf showing pax-b and krox20
expressing cells in the left part of the mid- and hindbrain displaced
from the midline. An intact hlx-1 stripe is present
anteriorly. The myoD staining of the paraxial mesoderm
suggest that the somite boundaries are out of register across the
midline and reveal a distinctly twisted midline. e and
f, dorsal views of embryos injected with h-EphA3 IV-VII
RNA, demonstrating normal expression of hlx-1,
pax-b, krox20 (c), and myoD
(d). The distinctive twist in the neuraxis of affected
embryos is missing and the pax-b and krox20
expressing cells are also symmetrically distributed lateral to the
midline.
|
|
The ability of h-EphA3 I-III but not of h-EphA3 IV-VII to mimic the
developmental disruption caused by h-EphA3 I-VII implies that the
subdomain responsible for mediating the specific, dominant negative
effect of the EphA3 ECD on zebrafish development is encoded in the
first three exons. This finding is consistent with assignment of the
ligand-binding domain to exon III by BIAcore analysis of ligand binding
affinities.
High Concentration of C-terminal Domain Protein Induces Disruption
of Somite Formation--
We observed a linear,
dose-dependent increase in the number of affected embryos
when the amount of injected h-EphA3 I-III RNA was increased from 1 to
100 ng per embryo, whereby the increase in defective embryos paralleled
the increase in concentration of the expressed protein (Fig.
5a). As before, only a small
number of defective embryos were observed at low and moderate
concentrations of h-EphA3 IV-VII RNA (1 and 10 pg/embryo, Fig. 4,
e and f and Fig. 5a), whereas at high
concentrations, the proportion of affected embryos injected with
sh-EphA3 IV-VII RNA was similar to the proportion of defective
sh-EphA3 I-III RNA-injected embryos (Fig. 5a, 100 pg/embryo). Importantly, the phenotype of animals injected with 100 pg
of sh-EphA3 IV-VII RNA was indistinguishable from the defects resulting from injection of either the entire h-EphA3 ECD or the ligand
binding domain alone, as judged by morphology and the expression of
marker genes (Fig. 5b). Thus the C-terminal portion of the receptor ECD encoded by exons IV-VII mediates a ligand-independent dominant negative effect on zebrafish somite formation and axial organization.

View larger version (65K):
[in this window]
[in a new window]
|
Fig. 5.
Dose-response of embryonic disruption to
injected h-EphA3 I-III or h-EphA3 IV-VII RNA. a, batches
of embryos (n = 29-107) were injected with decreasing
concentrations (from 100 to 1 pg) of h-EphA3 I-III ( ) or h-EphA3
IV-VII RNA ( ), and a constant amount of E-GFP mRNA (5 pg). The
embryos were allowed to grow for 12 to 13 hpf before fixation. They
were then hybridized with pax-b, hlx-1,
krox20, and myoD DIG-labeled riboprobes. Embryos
were observed under a dissecting microscope and scored for disrupted
patterns of gene expression. To control for potential defects due to
the genetic background of particular parents in our strain, a number of
embryos that were transferred to the injection stage were not injected
but were handled identically to the injected embryos and were scored as
described for defects. Parallel samples of h-EphA3 I-III RNA-injected
embryos were lysed at 10 hpf (10 embryos/100 µl), the exogenous
FLAG-tagged protein extracted on M2-agarose, and its concentration in
the lysate determined on an anti-h-EphA3 mAb-derivatized BIAcore
sensorchip. The concentration of h-EphA3 I-III per embryo is shown
( ). b, in situ hybridization analysis of 100 pg of h-EphA3 IV-VII RNA-injected embryo. An injected embryo at 12-13
h of development was fixed for in situ hybridization with
pax-b, hlx-1, krox20, and
myoD DIG-labeled riboprobes. The photograph
represents an antero-dorsal view with anterior to the top
and posterior to the bottom. Disorganization of
pax-b and krox20 expressing cells similar to the
pattern observed in h-EphA3 I-III RNA-injected embryos (Fig.
4d) is illustrated. Staining with myoD reveals
defects in somite organization, whereby open arrowheads
indicate missing somites in the right-hand part of the
embryo.
|
|
Transphosphorylation Assays Suggest Ligand-independent h-EphA3
Dimerization--
This dominant negative effect at high h-EphA3
IV-VII concentration can be explained by the occurrence of
heterodimers between intact endogenous receptors and the h-EphA3
IV-VII protein which are acting to block receptor function. This
notion, implying the existence of a dimerization interface outside the
ligand-binding region was supported by BIAcore analysis of the binding
of h-EphA3 I-VII, h-EphA3 I-III, and h-EphA3 IV-VII to a sensorchip
derivatized with h-EphA3. We demonstrated binding of h-EphA3 IV-VII at
micromolar concentrations that was characterized by a slow off rate,
yielding an apparent dissociation constant of 3 µM.
Marginally weaker binding was observed for the h-EphA3 IV-VII
construct, whereas the interaction of h-EphA3 I-III had a
substantially lower affinity (Table
I).
To test further the hypothesis of a dimerization interface, we
performed in vitro transphosphorylation assays of h-EphA3, constitutively expressed in LK 63 cells (29). Transphosphorylation of the receptor by cross-linking with anti-h-EphA3 mAb IIIA4 during immunoprecipitation or by incubation with mAb cross-linked
ephrin-A5·FLAG complexes has been demonstrated previously (3, 29). In
the latter experiments 20-30 nM ephrin-A5·mAb complex
had been used to induce receptor transphosphorylation. The
approximately 100-fold lower affinity of the receptor/receptor
interaction (Table I) compared with the ligand binding reaction (Fig.
1e) suggested that concentrations of the EphA5 constructs in
the 10-30 µM range would be necessary to inhibit
ligand-induced receptor transphosphorylation. As we were unable to
provide these high protein concentrations for this competition assay,
in an alternative approach we analyzed ligand-independent receptor
dimerization by assessing receptor binding of h-EphA5 constructs. Thus,
in the following experiments we prepared immune complexes of FLAG
peptide-tagged receptor ECD or the derived subdomain deletion
constructs with M2 antibody. These preformed, divalent receptor
ECD·M2 complexes were used at a low micromolar concentration to
induce receptor dimerization and transphosphorylation by the endogenous
receptor kinase. Incubation of LK63 cells with h-EphA3 I-VII·M2 mAb
complex resulted in a substantial phosphorylation of the endogenous
h-EphA3. This confirms that the soluble, exogenous mAb cross-linked
receptor dimer binds and tethers endogenous h-EphA3 receptors in the
absence of ligand and facilitates their transphosphorylation. The
interaction between the endogenous receptors and the exogenous receptor
ECD·M2 complex was sufficiently stable to withstand cell lysate and
immunoprecipitation with protein A-Sepharose (Fig.
6b, lane C). Importantly,
incubation of the cells with the h-EphA3 IV-VII subdomain gave a
virtually identical result (lane A), confirming that this
domain harbors the suggested receptor dimerization interface. Notably,
in both cases no additional phosphorylated h-EphA3 was recovered on
immunoprecipitation of the protein A-depleted lysates with anti-h-EphA3
mAb IIIA4 and confirms that only endogenous receptors, which had been
dimerized by the h-EphA3 IV-VII·M2 mAb complex, underwent
transphosphorylation. Western blot analysis with an anti-h-EphA3
polyclonal antiserum indicated that only a small (virtually
undetectable) proportion of the total endogenous receptor population
had been captured into the M2-protein A complex. In contrast to these
results, analysis of a parallel sample of the cells treated with an
identical concentration of h-EphA3 I-III·M2 complex (lane
B) revealed phosphorylated h-EphA3 in the anti-h-EphA3 mAb
precipitate but not in the protein A precipitate. This indicates that
h-EphA3 I-III can induce dimerization at high concentrations, but in
keeping with the BIAcore results, this interaction is notably weaker,
leading to dissociation of endogenous phosphorylated h-EphA3 from the
h-EphA3·M2 complex during cell lysis. In a control experiment, LK63
cells were treated with M2 mAb on its own, but yielded no
phosphorylated endogenous receptor in either the protein A or IIIA4
precipitates (lane D). Taken together, our experiments
suggest that the exon IV-VII-encoded subdomain with some contribution
of the exon III-encoded region provide the dimerization interface of
the h-EphA3 receptor, which is functional in the absence of ligand.

View larger version (35K):
[in this window]
[in a new window]
|
Fig. 6.
Transphosphorylation analysis of
ligand-independent receptor dimerization. Induction of
phosphorylation of endogenous h-EphA3 in parallel cultures of LK63
cells with preformed M2·mAb complexes of FLAG-tagged h-EphA3 IV-VII
(lane A), h-EphA3 I-III (lane B), or h-EphA3
I-VII (lane C). The endogenous receptor bound to the
exogenous receptor-subdomain complex is recovered by
immunoprecipitation with protein A (ProtA) and analyzed by
Western blot with PY20 anti-phosphotyrosine antibody (top
panel). The corresponding supernatant is extracted with
anti-h-EphA3 IIIA4 mAb and again analyzed by PY20 Western blot
(middle panel). This blot is stripped and further probed
with a polyclonal anti-h-EphA3 antiserum (bottom
panel).
|
|
 |
DISCUSSION |
While Eph receptors have been shown to mediate key functions in
embryogenesis, the mechanisms of ligand binding and receptor activation
underlying these functions remain to be defined in detail. It is clear
that only membrane-bound or artificially dimerized or clustered soluble
ligands will mediate activation of Eph receptors (43) including h-EphA3
(3), and soluble monomeric h-ephrin-A5 has been shown to act as
antagonist of receptor activation (2). Recently the role of higher
order receptor oligomers has been studied, demonstrating that full
biological activation is only achieved once a tetrameric receptor
aggregate is generated (22). Our analysis of the stoichiometry of
soluble h-ephrin A5 binding to the h-EphA3 ECD unambiguously confirmed
a one-to-one interaction (3). The event(s) that follow ligand binding,
leading to receptor oligomerization and cell signaling, remain to be
defined. This study sought to further our understanding of this first
step of receptor activation through the analysis of functional domains of the h-EphA3 ECD both in vitro and in vivo.
The highly conserved subdomain architecture of the ECD of Eph receptors
coincides with a conserved exon structure (this paper and Ref. 33). A
study of interspecies sequence homologies between human, murine, and
chicken EphA3 revealed high homology throughout but with a ranking of
exon sequence identities, the strongest evolutionary constraint (>99%
identity between mouse and human) being on exon III (Fig. 1,
a and b). Regions of the ECD demarcated by exon
boundaries were expressed in CHO cells, and the proteins were purified
to homogeneity. A kinetic analysis, using plasmon resonance detection
of binding of the various subdomains to BIAcore sensorchip-immobilized
h-ephrin-A5 clearly localized the ligand binding sequences to those
encoded by exons I-III. The affinity for the interaction of this
smaller ligand binding domain of KD = 18 nM was well within the range reported previously for the binding of ephrin-A5 to sensorchip-immobilized h-EphA3
(KD = 12 nM (3)) but was somewhat higher
than the affinity estimated for the binding of the h-EphA3 ECD to
sensorchip-immobilized ephrin-A5 (KD = 62-72
nM, Fig. 1e). Correspondingly increased
association rates of the smaller subdomain constructs (Fig.
1d) and of the ligand (3) suggest that higher diffusion
rates and improved access to the binding interface of the smaller
proteins may explain this apparent affinity increase.
In seeking to further narrow the binding region, we note that exon I
contributes only seven non-conserved residues, but both exons II and
III show very high sequence identity across species (Fig. 1). Attempts
to express exon III without exon II sequences were unsuccessful, and
expression of protein was not detected. However, in-solution
competition experiments with a peptide corresponding to the exon I- and
II-encoded residues of the receptor ECD showed no effect on binding.
Taken together with the homology data, these results suggest that exon
III-encoded sequences are directly involved in ligand binding, whereas
exon II is not involved but is required for a stable protein domain
structure. Furthermore, attempts to express a C-terminal truncated form
of exon III, terminating after cysteine 186 (corresponding to cysteine
191 of EphB2), resulted in low yields of high molecular weight protein
aggregates, suggesting the importance of this C-terminal sequence for
the structural integrity of this domain. These findings are in general
agreement with a recent study of the chicken EphB2 and EphA3 receptors
(36). By using a different approach the authors also identified the critical role of the N-terminal region in ligand binding. Although they
did not analyze the contribution to protein secretion, stability, or
ligand binding of the N-terminal, exon I- and II-encoded subdomain denoted in their report as "signal peptide," successful expression of N-terminally FLAG-tagged proteins in our study suggests that this
signal peptide is not cleaved from the receptor ECD during secretion.
Furthermore, restricted C-terminal truncations of exon III sequences in
their study resulted in reduced ligand binding affinity (36),
suggesting that most or all of exon III is required for high affinity
binding. Together, these findings, emphasizing the structural
importance of the N- and C-terminal sequences of the N-terminal half of
the EphA3 ECD, support our conclusion that exons II and III encode an
integral structure rather than, as previously assumed, discrete
globular and cysteine-rich subdomains.
Organization from defined structural building blocks with distinct
regions of sequence conservation is a common feature of RTKs (44). As
our data imply for EphA receptors, the region of highest sequence
conservation within several subfamilies including the fibroblast growth
factor receptors delineates the ligand-binding interface. In the case
of the fibroblast growth factor receptors, ligand binding is encoded by
Ig domains II and III, both of which independently bind fibroblast
growth factors. Similarly, the PDGFR, c-Kit, TrkR, and Flt1 RTKs use
multiple Ig repeats to bind ligand (21, 45-47), whereas the insulin R
ligand-binding site spans two unique N-terminal -subunit domains
(48) and ErbB binds EGF through the region between two Cys-rich
domains, with some contribution from the N terminus (49-51). In the
Eph family the ligand-binding site is characterized as a single
structural domain which, despite reported weak similarities to Ig-like
(4, 52) or laminin VI (36) domains, appears to be unique to this
family. The notion of a single exon II- and III-encoded protein domain is also supported by an evolutionary argument based on intron phase
analysis (53). The 5' end of exon II and the 3' end of exon III are
phase 1 (i.e. interrupting the coding triplet after one
base), whereas the intron between exons II and III is phase 0, implying
that it arose through insertion into an ancestral coding sequence.
To analyze further the role of isolated receptor ECD subdomains
in vivo, we modified a dominant negative strategy in
zebrafish, previously used to study EphA4 signaling in fore- and
hindbrain formation during zebrafish embryogenesis (24). Inhibition of RTK signaling by expression of kinase-deleted or truncated forms of the
receptor, either in a ligand-dependent (23, 24, 54) or
-independent manner (55, 56), is well established (reviewed in Ref.
44). We used our observation that expression of exogenous soluble EphA3
or ephrin-A5 resulted in a characteristic developmental defect in
somite development and axial organization4 to probe the
function of ECD subdomains. As anticipated from the BIAcore analysis,
embryos injected with h-EphA3 I-III RNA show the same phenotype as
h-EphA3 I-VII or soluble ephrin-A5 RNA-injected embryos, consistent
with a dominant negative effect by the soluble EphA3 ligand binding
domain. By contrast, injection of the h-EphA3 IV-VII RNA, encoding all
regions except the ligand-binding domain, was not expected to alter the
normal phenotype. At low and medium concentrations no abnormality in
embryo development was observed. Extended dose-response studies
revealed that both h-EphA3 I-VII or h-EphA3 I-III exhibited the
expected dose-dependent increase in the number of
developmentally defective embryos (Fig. 5).4 Although the
severity of the effects also increased (an increasing number of somites
were disrupted at higher concentrations of RNA; data not shown), the
defects were confined exclusively to those tissues that had been
perturbed also at low concentrations of injected RNA. Importantly, at
high concentrations of h-EphA3 IV-VII RNA and h-EphA3 I-III RNA,
injections resulted in a similar proportion of identically defective
embryos. The complete overlap of phenotypes resulting from these
injections of either h-EphA3 I-VII RNA, h-EphA3 I-III RNA, or high
concentrations of h-EphA3 IV-VII RNA implied that the same signaling
processes had been disrupted by all receptor constructs.
Since the h-EphA3 IV-VII protein cannot bind ephrin-A5 (Fig. 1,
d and e), this finding suggested that h-EphA3 can
bind to endogenous receptor to produce functionless heterodimers, thus disrupting Eph signaling in a ligand-independent manner. An
approximation of the abundance of the exogenous receptor proteins on
the basis of Western blot and BIAcore data (Figs. 2, a and
b, 5a), and by assuming the extracellular space
of a 10 hpf embryo as 5 pl (1/100th of the total volume of a 1-mm
diameter embryo), suggests a concentration of 10-20 µM
h-EphA3 IV-VII in 100 pg of mRNA-injected embryos. This high
concentration of expressed protein required to achieve the dominant
negative effect (Fig. 5, a and b) implies a
significantly lower affinity of the receptor/receptor interaction than
for the receptor-ligand binding. This notion was confirmed by BIAcore studies of h-EphA3 I-VII or h-EphA3 IV-VII binding to h-EphA3 I-VII
derivatized sensor surfaces, indicating that ligand-independent receptor dimerization occurred at micromolar concentrations (Table I).
Although we were not able to achieve high enough concentrations of
monomeric h-EphA3 IV-VII to block ligand-induced h-EphA3
transphosphorylation in LK63 cells, we confirmed the ligand-independent
receptor dimerization through a direct in vitro binding
experiment. Anti-FLAG mAb cross-linked forms of either soluble h-EphA3
I-VII or the ligand binding domain-deficient h-EphA3 IV-VII construct
(Fig. 6) induced transphosphorylation of endogenous receptors,
demonstrating their competence for a ligand-independent interaction. A
slow dissociation rate from the h-EphA3 I-VII sensor surface during
BIAcore experiments and immunoprecipitation of phosphorylated
endogenous h-EphA3 with mAb-dimerized h-EphA3 ECD constructs from a
detergent lysate of LK63 cells suggest that the interaction is stable,
once the critical receptor concentration is reached. On the other hand,
a weak interaction of h-EphA3 I-III with h-EphA3 I-VII inferred from
BIAcore and transphosphorylation experiments (Table I, Fig. 6) did not
withstand the immunoprecipitation and indicates a minor contribution of this domain to the dimerization. Thus, our experiments provide several
lines of evidence suggesting the presence of a low affinity dimerization domain which is encoded by exons IV-VII and functions independently of ligand binding. Exons IV-VII encode an EGF domain and
two Fibronectin type III domains, the latter having been implicated in
receptor dimerization in the cytokine receptor family (57). Although
the data presented in this report do not precisely define the region
mediating dimerization, preliminary zebrafish studies with h-EphA3
IV-V and h-EphA3 V-VII suggest that dimerization is mediated by exon
IV sequences.
The presence of a ligand-independent dimerization domain in EphA3
invites comparison with activation of the c-Kit and PDGFR. Experiments
with c-Kit-specific mAbs which block dimerization, and analysis of
c-Kit ECD deletion mutants, define an Ig domain C-terminal to the
ligand binding interface which is required for receptor dimerization
(21). This dimerization domain is essential for biological effects of
the Kit ligand. Of most relevance to the results presented,
ligand-independent activation at high receptor density has been
demonstrated using high level expression of PDGFR in SF9 cells
(25).
The identification of distinct receptor subdomains that mediate
ligand-binding and receptor dimerization at different concentrations suggests a stepwise mechanism of receptor activation for EphA receptors
and ephrin-A ligands. In our model, an EphA-expressing cell or axon
moving into a gradient generated by differentially expressing
ephrin-A-positive cells encounters progressively higher ephrin-A
concentrations. As EphA receptors engage ephrin through high affinity
interaction of the N-terminal ligand-binding domain at the cell-cell
interface (step 1), the reduced mobility of the receptor-ligand
complexes versus free receptor or ligand results in their
accumulation at the interface. At some position in the ephrin-A
gradient, a critical receptor concentration (dependent on
receptor-ligand affinity) obtains at the interface between the cells
such that receptor-receptor interaction through the C-terminal
dimerization domain (step 2) allows the generation of multimeric
complexes. EphA signaling is activated by transphosphorylation of the
oligomerized receptors (step 3), and the resulting signal halts
migration of the EphA-expressing cell. Recent observations indicating
that multimeric complexes (tetramers) of EphB1 and EphB2 receptors are
required for full biological function (22) is of interest in regard to
the experiments presented here, in which transphosphorylation is
induced by heterotetramer formation and might involve even higher order
aggregates. It seems reasonable to speculate that the low affinity
dimerization domain is involved in mediating the formation of these
higher order structures and thus provides a critical component of the
Eph-receptor signaling system.
 |
ACKNOWLEDGEMENTS |
We thank Caroline Brennan and Nigel Holder
for helpful discussions and critical comments on the manuscript. Thanks
to Jacqueline Gad and Helen Cooper for sharing unpublished results and
to Janna Stickland for preparation of figures.
 |
FOOTNOTES |
*
This work was supported in part by the National Health and
Medical Research Council of Australia, the Leukaemia Foundation of
Queensland, the Queensland Cancer Fund, and the Australian Government
Cooperative Research Centres scheme.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
Recipient of an Anti-cancer Councel of Victoria Postgraduate
Research Scholarship.
To whom correspondence should be addressed: Queensland
Institute for Medical Research, The Bancroft Centre, Post Office, Royal Brisbane Hospital, 4029, Queensland, Australia. E-mail:
andrewBo{at}qimr.edu.au.
The abbreviations used are:
ECD, extracellular
domain; DCC, deleted in colo-rectal cancer; FLAGTM, refers
to the amino acid sequence DYKDDDDKmAb, monoclonal antibodyPAGE, polyacrylamide electrophoresisRTK, receptor tyrosine kinasesh-EphA3, soluble h-EphA3 extracellular domainPDGFR, platelet-derived
growth factor receptorEGF, epidermal growth factorCHO, Chinese
hamster ovaryPCR, polymerase chain reactionbp, base pairoligos, oligonucleotideshpf, hours post-fertilizationGFP, green
fluorescent proteinDIG, digoxigenin.
2
M. Dottori and A. W. Boyd, unpublished
observations.
3
M. Lackmann and L. Kravets, unpublished
observations.
4
M. Lackmann, A. C. Oates, M. Dottori,
F. M. Smith, C. Do, L. Kravets, C. Brennan, M. Power, N. Holder,
and A. W. Boyd, manuscript submitted for publication.
5
J. M. Gad and H. M. Cooper, personal
communication.
 |
REFERENCES |
-
Davis, S.,
Gale, N. W.,
Aldrich, T. H.,
Maisonpierre, P. C.,
Lhotak, V.,
Pawson, T.,
Goldfarb, M.,
and Yancopoulos, G. D.
(1994)
Science
266,
816-819[Abstract/Free Full Text]
-
Winslow, J. W.,
Moran, P.,
Valverde, J.,
Shih, A.,
Yuan, J. Q.,
Wong, S. C.,
Tsai, S. P.,
Goddard, A.,
Henzel, W. J.,
Hefti, F.,
Beck, K. D.,
and Caras, J. W.
(1995)
Neuron
14,
973-981[CrossRef][Medline]
[Order article via Infotrieve]
-
Lackmann, M.,
Mann, R. J.,
Kravets, L.,
Smith, F. M.,
Bucci, T. A.,
Maxwell, K. F.,
Howlett, G. J.,
Olsson, J. E.,
Vanden Bos, T.,
Cerretti, D. P.,
and Boyd, A. W.
(1997)
J. Biol. Chem.
272,
16521-16530[Abstract/Free Full Text]
-
Tuzi, N. L.,
and Gullick, W. J.
(1994)
Br. J. Cancer
69,
417-421[Medline]
[Order article via Infotrieve]
-
Henkemeyer, M.,
Marengere, L. E.,
McGlade, J.,
Olivier, J. P.,
Conlon, R. A.,
Holmyard, D. P.,
Letwin, K.,
and Pawson, T.
(1994)
Oncogene
9,
1001-1014[Medline]
[Order article via Infotrieve]
-
Pandey, A.,
Lindberg, R. A.,
and Dixit, V. M.
(1995)
Curr. Biol.
5,
986-989[CrossRef][Medline]
[Order article via Infotrieve]
-
The Eph Nomenclature Committee.
(1997)
Cell
90,
403-404[CrossRef][Medline]
[Order article via Infotrieve]
-
Beckmann, M. P.,
Cerretti, D. P.,
Baum, P.,
Vanden Bos, T.,
James, L.,
Farrah, T.,
Kozlosky, C.,
Hollingsworth, T.,
Shilling, H.,
Maraskovsky, E.,
Fletcher, F. A.,
Lhotak, V.,
Pawson, T.,
and Lyman, S. D.
(1994)
EMBO J.
13,
3757-3762[Medline]
[Order article via Infotrieve]
-
Pandey, A.,
Lazar, D. F.,
Saltiel, A. R.,
and Dixit, V. M.
(1994)
J. Biol. Chem.
269,
30154-30157[Abstract/Free Full Text]
-
Cerretti, D. P.,
Vanden Bos, T.,
Nelson, N.,
Kozlosky, C. J.,
Reddy, P.,
Maraskovsky, E.,
Park, L. S.,
Lyman, S. D.,
Copeland, N. G.,
Gilbert, D. J.,
Jenkin, N. A.,
and Fletcher, F. A.
(1995)
Mol. Immunol.
32,
1197-1205[CrossRef][Medline]
[Order article via Infotrieve]
-
Pandey, A.,
Duan, H.,
and Dixit, V. M.
(1995)
J. Biol. Chem.
270,
19201-19204[Abstract/Free Full Text]
-
Brambilla, R.,
Schnapp, A.,
Casagranda, F.,
Labrador, J. P.,
Bergemann, A. D.,
Flanagan, J. G.,
Pasquale, E. B.,
and Klein, R.
(1995)
EMBO J.
14,
3116-3126[Medline]
[Order article via Infotrieve]
-
Cheng, H. J.,
and Flanagan, J. G.
(1994)
Cell
79,
157-168[CrossRef][Medline]
[Order article via Infotrieve]
-
Monschau, B.,
Kremoser, C.,
Ohta, K.,
Tanaka, H.,
Kaneko, T.,
Yamada, T.,
Handwerker, C.,
Hornberger, M. R.,
Loschinger, J.,
Pasquale, E. B.,
Siever, D. A.,
Verderame, M. F.,
Muller, B. K.,
Bonhoeffer, F.,
and Drescher, U.
(1997)
EMBO J.
16,
1258-1267[CrossRef][Medline]
[Order article via Infotrieve]
-
Cheng, H. J.,
Nakamoto, M.,
Bergemann, A. D.,
and Flanagan, J. G.
(1995)
Cell
82,
371-381[CrossRef][Medline]
[Order article via Infotrieve]
-
Drescher, U.,
Kremoser, C.,
Handwerker, C.,
Loschinger, J.,
Noda, M.,
and Bonhoeffer, F.
(1995)
Cell
82,
359-370[CrossRef][Medline]
[Order article via Infotrieve]
-
Nakamoto, M.,
Cheng, H. J.,
Friedman, G. C.,
McLaughlin, T.,
Hansen, M. J.,
Yoon, C. H.,
O'Leary, D. M.,
and Flanagan, J. G.
(1996)
Cell
86,
755-766[CrossRef][Medline]
[Order article via Infotrieve]
-
Frisen, J.,
Yates, P. A.,
McLaughlin, T.,
Friedman, G. C.,
O'Leary, D. D. M.,
and Barbacid, M.
(1998)
Neuron
20,
235-243[CrossRef][Medline]
[Order article via Infotrieve]
-
Brennan, C.,
Monschau, B.,
Lindberg, R.,
Guthrie, B.,
Drescher, U.,
Bonhoeffer, F.,
and Holder, N.
(1997)
Development
124,
655-664[Abstract]
-
Ullrich, A.,
and Schlessinger, J.
(1990)
Cell
61,
203-212[CrossRef][Medline]
[Order article via Infotrieve]
-
Blechman, J. M.,
Lev, S.,
Barg, J.,
Eisenstein, M.,
Vaks, B.,
Vogel, Z.,
Givol, D.,
and Yarden, Y.
(1995)
Cell
80,
103-113[CrossRef][Medline]
[Order article via Infotrieve]
-
Stein, E.,
Huynh-Do, U.,
Lane, A. A.,
Cerretti, D. P.,
and Daniel, T. O.
(1998)
J. Biol. Chem.
273,
1303-1308[Abstract/Free Full Text]
-
Xu, Q.,
Alldus, G.,
Holder, N.,
and Wilkinson, D. G.
(1995)
Development
121,
4005-4016[Abstract]
-
Xu, Q.,
Alldus, G.,
Macdonald, R.,
Wilkinson, D. G.,
and Holder, N.
(1996)
Nature
381,
319-322[CrossRef][Medline]
[Order article via Infotrieve]
-
Herren, B.,
Rooney, B.,
Weyer, K. A.,
Iberg, N.,
Schmid, G.,
and Pech, M.
(1993)
J. Biol. Chem.
268,
15088-15095[Abstract/Free Full Text]
-
Sajjadi, F. G.,
Pasquale, E. B.,
and Subramani, S.
(1991)
New Biol.
3,
769-778[Medline]
[Order article via Infotrieve]
-
Sambrook, J.,
Fritsch, E. F.,
and Manniatis, T.
(1989)
Molecular Cloning: A Laboratory Manual, pp. 2.82-2.118, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
-
Lackmann, M.,
Bucci, T.,
Mann, R. J.,
Kravets, L. A.,
Viney, E.,
Smith, F.,
Moritz, R. L.,
Carter, W.,
Simpson, R. J.,
Nicola, N. A.,
Mackwell, K.,
Nice, E. C.,
Wilks, A. F.,
and Boyd, A. W.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
2523-2527[Abstract/Free Full Text]
-
Boyd, A. W.,
Ward, L. D.,
Wicks, I. P.,
Simpson, R. J.,
Salvaris, E.,
Wilks, A.,
Welch, K.,
Loudovaris, M.,
Rockman, S.,
and Busmanis, I.
(1992)
J. Biol. Chem.
267,
3262-3267[Abstract/Free Full Text]
-
Westerfield, M.
(1995)
The Zebrafish Book, University of Oregon Press
-
Kimmel, C. B.,
Ballard, W. W.,
Kimmel, S. R.,
Ullmann, B.,
and Schilling, T. F.
(1995)
Dev. Dyn.
203,
253-310[Medline]
[Order article via Infotrieve]
-
Salvaris, E.,
Novotny, J. R.,
Welch, K.,
Campbell, L.,
and Boyd, A. W.
(1992)
Leuk. Res.
16,
655-663[CrossRef][Medline]
[Order article via Infotrieve]
-
Connor, R. J.,
and Pasquale, E. B.
(1995)
Oncogene
11,
2429-2438[Medline]
[Order article via Infotrieve]
-
Maisonpierre, P. C.,
Barrezueta, N. X.,
and Yancopoulos, G. D.
(1993)
Oncogene
8,
3277-3288[Medline]
[Order article via Infotrieve]
-
Williams, A. F.,
and Barclay, A. N.
(1988)
Annu. Rev. Immunol.
6,
381-405[Medline]
[Order article via Infotrieve]
-
Labrador, J. P.,
Brambilla, R.,
and Klein, R.
(1997)
EMBO J.
16,
3889-3897[CrossRef][Medline]
[Order article via Infotrieve]
-
Stanley, P.
(1989)
Mol. Cell. Biol.
9,
377-383[Abstract/Free Full Text]
-
Cooper, H. M.,
Armes, P.,
Britto, J.,
Gad, J.,
and Wilks, A. F.
(1995)
Oncogene
11,
2243-2254[Medline]
[Order article via Infotrieve]
-
Fjose, A.,
Izpisua-Belmonte, J. C.,
Fromental-Ramain, C.,
and Duboule, D.
(1994)
Development
120,
71-81[Abstract]
-
Krauss, S.,
Johansen, T.,
Korzh, V.,
and Fjose, A.
(1991)
Development
113,
1193-1206[Abstract]
-
Oxtoby, E.,
and Jowett, T.
(1993)
Nucleic Acids Res.
21,
1087-1095[Abstract/Free Full Text]
-
Weinberg, E. S.,
Allende, M. L.,
Kelly, C. S.,
Abdelhamid, A.,
Murakami, T.,
Andermann, P.,
Doerre, O. G.,
Grunwald, D. J.,
and Riggleman, B.
(1996)
Development
122,
271-280[Abstract]
-
Tessier-Lavigne, M.
(1995)
Cell
82,
345-348[CrossRef][Medline]
[Order article via Infotrieve]
-
van der Geer, P.,
and Hunter, T.
(1994)
Annu. Rev. Cell Biol.
10,
251-337[CrossRef]
-
Heidaran, M. A.,
Pierce, J. H.,
Jensen, R. A.,
Matsui, T.,
and Aaronson, S. A.
(1990)
J. Biol. Chem.
265,
18741-18744[Abstract/Free Full Text]
-
Davis-Smyth, T.,
Chen, H.,
Park, J.,
Presta, L. G.,
and Ferrara, N.
(1996)
EMBO J.
15,
4919-4927[Medline]
[Order article via Infotrieve]
-
Perez, P.,
Coll, P. M.,
Hempstead, B. L.,
Martin-Zanca, D.,
and Chao, M. V.
(1995)
Mol. Cell. Neurosci.
6,
97-105[CrossRef][Medline]
[Order article via Infotrieve]
-
Wedekind, F.,
Baer-Pontzen, K.,
Bala-Mohan, S.,
Choli, D.,
Zahn, H.,
and Brandenburg, D.
(1989)
Biol. Chem. Hoppe-Seyler
370,
251-258[Medline]
[Order article via Infotrieve]
-
Lax, I.,
Burgess, W. H.,
Bellot, F.,
Ullrich, A.,
Schlessinger, J.,
and Givol, D.
(1988)
Mol. Cell. Biol.
8,
1831-1834[Abstract/Free Full Text]
-
Lax, I.,
Bellot, F.,
Howk, R.,
Ullrich, A.,
Givol, D.,
and Schlessinger, J.
(1989)
EMBO J.
8,
421-427[Medline]
[Order article via Infotrieve]
-
Woltjer, R. L.,
Lukas, T. J.,
and Staros, J. V.
(1992)
Proc. Natl. Acad. Sci. U. S. A.
89,
7801-7805[Abstract/Free Full Text]
-
Pandey, A.,
Shao, H.,
Marks, R. M.,
Polverini, P. J.,
and Dixit, V. M.
(1995)
Science
268,
567-569[Abstract/Free Full Text]
-
Patthy, L.
(1987)
FEBS Lett.
214,
1-7[CrossRef][Medline]
[Order article via Infotrieve]
-
Ueno, H.,
Escobedo, J. A.,
and Williams, L. T.
(1993)
J. Biol. Chem.
268,
22814-22819[Abstract/Free Full Text]
-
Frattali, A. L.,
Treadway, J. L.,
and Pessin, J. E.
(1992)
J. Biol. Chem.
267,
19521-19528[Abstract/Free Full Text]
-
Levy-Toledano, R.,
Caro, L. H.,
Accili, D.,
and Taylor, S. I.
(1994)
EMBO J.
13,
835-842[Medline]
[Order article via Infotrieve]
-
Somers, W.,
Ultsch, M.,
De Vos, A. M.,
and Kossiakoff, A. A.
(1994)
Nature
372,
478-481[CrossRef][Medline]
[Order article via Infotrieve]
-
Wicks, I. P.,
Wilkinson, D.,
Salvaris, E.,
and Boyd, A. W.
(1992)
Proc. Natl. Acad. Sci. U. S. A.
89,
1611-1615[Abstract/Free Full Text]
-
Dayhoff, M. O.,
Barker, W. C.,
and Hunt, L. T.
(1983)
Methods Enzymol.
91,
524-595[Medline]
[Order article via Infotrieve]
-
Bell, G. I.,
Fong, N. M.,
Stempien, M. M.,
Wormsted, M.,
Caput, D.,
Ku, L.,
Urdea, M. S.,
Rall, L. B.,
and Sanchez-Pescador, R.
(1986)
Nucleic Acids Res.
14,
8427-8446[Abstract/Free Full Text]
-
Oldberg, A.,
and Ruoslahti, E.
(1986)
J. Biol. Chem.
261,
2113-2116[Abstract/Free Full Text]
-
Mount, S. M.
(1982)
Nucleic Acids Res.
10,
459-472[Abstract/Free Full Text]
Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
A. Schmandke, A. Schmandke, and S. M. Strittmatter
ROCK and Rho: Biochemistry and Neuronal Functions of Rho-Associated Protein Kinases
Neuroscientist,
October 1, 2007;
13(5):
454 - 469.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Kertesz, V. Krasnoperov, R. Reddy, L. Leshanski, S. R. Kumar, S. Zozulya, and P. S. Gill
The soluble extracellular domain of EphB4 (sEphB4) antagonizes EphB4-EphrinB2 interaction, modulates angiogenesis, and inhibits tumor growth
Blood,
March 15, 2006;
107(6):
2330 - 2338.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Vearing, F.-T. Lee, S. Wimmer-Kleikamp, V. Spirkoska, C. To, C. Stylianou, M. Spanevello, M. Brechbiel, A. W. Boyd, A. M. Scott, et al.
Concurrent Binding of Anti-EphA3 Antibody and Ephrin-A5 Amplifies EphA3 Signaling and Downstream Responses: Potential as EphA3-Specific Tumor-Targeting Reagents
Cancer Res.,
August 1, 2005;
65(15):
6745 - 6754.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Day, C. To, J.-P. Himanen, F. M. Smith, D. B. Nikolov, A. W. Boyd, and M. Lackmann
Three Distinct Molecular Surfaces in Ephrin-A5 Are Essential for a Functional Interaction with EphA3
J. Biol. Chem.,
July 15, 2005;
280(28):
26526 - 26532.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. K. Murai and E. B. Pasquale
Eph Receptors, Ephrins, and Synaptic Function
Neuroscientist,
August 1, 2004;
10(4):
304 - 314.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
D. A. Feldheim, M. Nakamoto, M. Osterfield, N. W. Gale, T. M. DeChiara, R. Rohatgi, G. D. Yancopoulos, and J. G. Flanagan
Loss-of-Function Analysis of EphA Receptors in Retinotectal Mapping
J. Neurosci.,
March 10, 2004;
24(10):
2542 - 2550.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. M. Smith, C. Vearing, M. Lackmann, H. Treutlein, J. Himanen, K. Chen, A. Saul, D. Nikolov, and A. W. Boyd
Dissecting the EphA3/Ephrin-A5 Interactions Using a Novel Functional Mutagenesis Screen
J. Biol. Chem.,
March 5, 2004;
279(10):
9522 - 9531.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. H. Wimmer-Kleikamp, P. W. Janes, A. Squire, P. I.H. Bastiaens, and M. Lackmann
Recruitment of Eph receptors into signaling clusters does not require ephrin contact
J. Cell Biol.,
March 1, 2004;
164(5):
661 - 666.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Walker-Daniels, A. R. Hess, M. J.C. Hendrix, and M. S. Kinch
Differential Regulation of EphA2 in Normal and Malignant Cells
Am. J. Pathol.,
April 1, 2003;
162(4):
1037 - 1042.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
U. Huynh-Do, C. Vindis, H. Liu, D. P. Cerretti, J. T. McGrew, M. Enriquez, J. Chen, and T. O. Daniel
Ephrin-B1 transduces signals to activate integrin-mediated migration, attachment and angiogenesis
J. Cell Sci.,
January 8, 2002;
115(15):
3073 - 3081.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. D. Lawrenson, S. H. Wimmer-Kleikamp, P. Lock, S. M. Schoenwaelder, M. Down, A. W. Boyd, P. F. Alewood, and M. Lackmann
Ephrin-A5 induces rounding, blebbing and de-adhesion of EphA3-expressing 293T and melanoma cells by CrkII and Rho-mediated signalling
J. Cell Sci.,
January 3, 2002;
115(5):
1059 - 1072.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. W. Boyd and M. Lackmann
Signals from Eph and Ephrin Proteins: A Developmental Tool Kit
Sci. Signal.,
December 11, 2001;
2001(112):
re20 - re20.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Y. Li, Z. Mi, Y. Feng, C. F. McTiernan, R. Zhou, P. D. Robbins, S. C. Watkins, and A. M. Feldman
Differential effects of overexpression of two forms of ephrin-A5 on neonatal rat cardiomyocytes
Am J Physiol Heart Circ Physiol,
December 1, 2001;
281(6):
H2738 - H2746.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Gu and S. Park
The EphA8 Receptor Regulates Integrin Activity through p110{gamma} Phosphatidylinositol-3 Kinase in a Tyrosine Kinase Activity-Independent Manner
Mol. Cell. Biol.,
July 15, 2001;
21(14):
4579 - 4597.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. D. Chong, E. K. Park, E. Latimer, R. Friesel, and I. O. Daar
Fibroblast Growth Factor Receptor-Mediated Rescue of x-Ephrin B1-Induced Cell Dissociation in Xenopus Embryos
Mol. Cell. Biol.,
January 15, 2000;
20(2):
724 - 734.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
N Holder and R Klein
Eph receptors and ephrins: effectors of morphogenesis
Development,
January 5, 1999;
126(10):
2033 - 2044.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
T. C. Woods, C. R. Blystone, J. Yoo, and E. R. Edelman
Activation of EphB2 and Its Ligands Promotes Vascular Smooth Muscle Cell Proliferation
J. Biol. Chem.,
January 11, 2002;
277(3):
1924 - 1927.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 1998 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|